ST. LOUIS, Jan. 14 /PRNewswire-FirstCall/ -- At the Boston Atrial Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: STXS) will showcase three advances in remote magnetic ablation that it believes will enhance the efficiency, performance and versatility of its Niobe(R) Magnetic Navigation System. In booth #917, Stereotaxis will exhibit its new software platform, Navigant 3.0, with the QuikCAS(TM) Cardiodrive(R) System for enhanced remote catheter control and improved EP lab workflow, and its partnered magnetic irrigated catheter, which is now available in Europe.
"Together these three products represent a significant advancement in remote cardiovascular procedures," said Michael P. Kaminski, Stereotaxis President and CEO.
-- The QuikCAS Cardiodrive System remotely advances and retracts the catheter in the patient's heart while the Niobe magnets precisely steer the catheter's distal tip. The QuikCAS advancements provide the clinician with greater responsiveness for enhanced performance, a more ergonomic design and faster set-up for improved workflow.
-- Stereotaxis' partnered magnetic irrigated catheter, now available in Europe, is widely recognized as the gold standard for complex ablations such as ventricular tachycardia and complex left atrial arrhythmias. European clinicians have treated more than 600 patients with the magnetic irrigated catheter, with extremely positive results. Stereotaxis has prepared a monograph of these results and will be highlighting the data at the Symposium.
-- Navigant 3.0 is Stereotaxis' new software platform for its Niobe Magnetic Navigation System. It provides users with many enhanced features and new capabilities that simplify and accelerate its use, including automated registration of the 3D mapping system and calibration of the Cardiodrive System; faster and more accurate automation with re-targeting to compensate for patient movement; and broader integration with other EP Lab systems. Particularly when used in combination with Odyssey(TM), Stereotaxis believes that Navigant 3.0 will significantly advance EP lab productivity and procedural workflow efficiency.
In addition, clinicians can test drive the full Odyssey information management solution including its new Odyssey Workstation 3.0 software and the Odyssey Cinema(TM) data management system for remote viewing and recording of live interventional cases. From an Odyssey Workstation in booth 917, clinicians will be able to control a catheter in a beating heart phantom located 1,200 miles away in the company's St. Louis headquarters. Alongside the Odyssey Workstation, clinicians can experience Odyssey Cinema for remote viewing, recording, playback and annotation of synchronized lab information showing the full context of the procedure. Odyssey Cinema can then broadcast their case through an Odyssey Connect network link to another hospital on the global Odyssey network, or during this conference to a partner's booth across the exhibit hall, allowing clinicians to experience the clear advantages of the Odyssey network for clinical collaboration, remote consultation, and training.
"Some 18,000 procedures performed with the Niobe Magnetic Navigation System have established its reputation for clinical safety, utility, and efficacy," said Mr. Kaminski. "We continue to innovate and deliver the most powerful combination of products available to the electrophysiologist, and are positioned to revolutionize the interventional lab with automation, information management, and networking."
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.
This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.
|SOURCE Stereotaxis, Inc.|
Copyright©2009 PR Newswire.
All rights reserved